Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) moved down -30.41% and closed its last trading session at $1.03. This Medical Sector stock currently has the Market Capitalization of 33 Million. The Average Volume for the stock is measured as 1.59 Million. The Stock has a 52-Week High of $4.58 and 52-Week Low of $0.43 following the dates, it touched its 52-Week High on Jun 9, 2016 and 52-Week Low on Nov 30, 2016. Currently, the Return on Assets value for the trailing twelve months is -86.6% with the Return on Equity and Return on Investment of -119.1% and 0% respectively. This firm currently has YTD (year to date) performance of 98.08 Percent which is awesome. The Short Ratio for the stock is 1.64.
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-1.6. The TTM operating margin is 0 percent.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) beats earnings by 77%, The Stock Missed Earnings 1 times and has met earnings 1 times.
We will discuss the past Quarters Earnings below:
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) reported its previous quarter on 11/08/2016 where it reported the Actual Earnings of $-0.36. The Closing price before the company posted its earnings was $1.02. The Stock declined on the very next day of earnings and maintained its stock price at $0.95 by showing a % change of -6.86 percent from its previous closing price. The Next Day Volume after Earnings was reported as 103322. On the 7th day After Earnings Report, the stock hit its share price as $1.02 by showing 0% increase from the Stock price Before Earnings were reported.
On 08/09/2016, the stock reported the EPS of $-0.3 where Analysts were projecting the EPS to be $-0.42 showing a difference of $0.12. Thus Surprise Factor was there with 28.6 percent. Before Earnings Announcement on 08/09/2016, the firm had its stock price of $1.55. And immediately on the next day after earnings announcement, the stock inclined 1.29% and closed its trading session at $1.57. On 7th Day after earnings release, Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) dropped to -2.58% from $1.55 to $1.51.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates include INOpulse, a pulsatile nitric oxide delivery device, which has completed Phase II clinical trials for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases; and bioabsorbable cardiac matrix, a medical device for the prevention of congestive heart failure. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.